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Available online 27 September 2013Abstract Today, the tool that is most commonly used to evaluate the osteogenic differentiation of bone marrow stromal cells
(BMSCs) in vitro is the demonstration of the expression of multiple relevant markers, such as ALP, RUNX2 and OCN. However, as
yet, there is no single surface marker or panel of markers which clearly defines human BMSCs (hBMSCs) differentiating towards
the osteogenic lineage. The aim of this study was therefore to examine this issue.
Stable isotope labeling by amino acids in cell culture (SILAC)-based quantitative proteomics was utilized to investigate differently
expressed surface markers in osteogenically differentiated and undifferentiated hBMSCs. Labeled membrane proteins were
analyzed by mass spectrometry (MS) and 52 proteins with an expression ratio above 2, between osteogenically differentiated and
undifferentiated cells, were identified. Subsequent validation, by flow cytometry and ELISA, of the SILAC expression ratios for a
number of these proteins and investigations of the lineage specificity of three candidate markers were performed.
The surface markers, CD10 and CD92, demonstrated significantly increased expression in hBMSCs differentiated towards the
osteogenic and adipogenic lineages. In addition, there was a slight increase in CD10 expression during chondrogenic differentiation.
Furthermore, the expression of the intracellular protein, crystalline-αB (CRYaB), was only significantly increased in osteogenically
differentiated hBMSCs and not affected during differentiation towards the chondrogenic or adipogenic lineages.⁎ Corresponding author at: Department of Biomaterials, University of Gothenburg, Box 412, SE-405 30 Gothenburg, Sweden. Fax: +46 31 786 29
41.
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154 C. Granéli et al.It has been concluded from the present results that CD10 and CD92 are potential markers of osteogenic and adipogenic
differentiation and that CRYaB is a potential novel osteogenic marker specifically expressed during the osteogenic
differentiation of hBMSCs in vitro.
© 2013 The Authors. Published by Elsevier B.V. Open access under the  license.CC BY-NC-SAIntroduction
Bone marrow stromal cells (BMSCs), also known as mesen-
chymal stem cells or mesenchymal stromal cells (MSCs), are
multipotent stem cells with a high proliferation capacity and
the ability to differentiate into cells of the connective tissue
lineage, such as adipocytes, osteoblasts and chondrocytes,
both in vitro and in vivo (Barry and Murphy, 2004; Caplan and
Bruder, 2001; Dominici et al., 2006; Pittenger et al., 1999).
Human BMSCs (hBMSCs) are found in stem cell niches in bone
marrow, but cells referred to as MSCs can also be found in
adipose tissue, in connective tissue of the umbilical cord and
in cord blood. Although the populations isolated from these
different sources are similar to one another, they display
variations in both differentiation potential and phenotype
(Abdallah and Kassem, 2007; Baksh et al., 2007; Chang et al.,
2006; Kern et al., 2006; Wang et al., 2004, 2009). Moreover,
within each MSC population, there is phenotypic variance and
these cells are generally not regarded as a homogeneous
population (Bianco et al., 2013). As a result, severalmarkers are
used to define hBMSCs. A panel of both positive and negative
markers, together with tri-lineage potency and plastic adher-
ence, has been suggested as the minimum criterion in order to
classify a cell population as hBMSCs (Dominici et al., 2006). The
positive markers include CD166, CD90, CD105 and Stro-1.
Furthermore, the hBMSCs should be negative for hematopoietic
markers, such as CD14, CD34, CD45 and HLA-DR (Abdallah and
Kassem, 2007; Komori, 2006; Nishimura et al., 2008).
The maturation of hBMSCs into osteoblasts, i.e. osteogenic
differentiation, is pivotal in bone growth, fracture healing and
the osseointegration of bone-anchored implants, as well as the
general bone turnover process, governed by the interactions
between osteocytes, osteoblasts and osteoclasts. The differen-
tiation process towards osteoblasts is regulated by a number of
key factors and signaling pathways. Someof the factors involved
are commonly used as markers, at both gene and protein level,
of hBMSCs differentiating into osteoblasts. One such example is
runt-related transcription factor 2 (RUNX2) and it is often
referred to as the master switch of osteogenic differentiation.
RUNX2 is crucial for the generation of amineralized tissue (Deng
et al., 2008; Ducy et al., 2000) and its gene expression is usually
analyzed during the early phases of osteogenic differentiation.
Another important marker is the effector protein, alkaline
phosphatase (ALP), which is responsible for the mineralization
of the extracellular matrix (ECM) (Marom et al., 2004). Both the
mRNA and protein expression of ALP can be used to describe
osteogenic differentiation progression. However, the use of ALP
enzyme activity assays is most common. Furthermore, the main
constituent of the organic part of the ECM is collagen type I, but
it is the two non-collagenous bone ECM proteins, osteopontin
(OPN) and osteocalcin (OCN), that are commonly used as early
and late markers of osteogenic differentiation respectively
(Aubin, 2001).Recently, efforts have been made to identify differently
expressed proteins during the osteogenic differentiation of
hBMSCs (Alves et al., 2010; Foster et al., 2005; Kim et al.,
2008, 2010; Ong and Mann, 2006; Zhang et al., 2007). These
types of studies will not only increase our understanding of the
proteins and signaling pathways involved in the differenti-
ation process, they could also reveal new, reliable markers
of hBMSCs undergoing osteogenic differentiation. Surface
markers in particular could be an essential tool for monitoring
the differentiation process in future applications, such as cell
therapy and tissue engineering, as they are accessible using
non-disruptive techniques such as flow cytometry. However, to
date, there is no single CD marker or panel of markers, similar
to that used for defining undifferentiated hBMSCs, which is
able clearly to define a population of hBMSCs differentiating
towards the osteogenic lineage.
A method for quantitatively measuring changes in protein
expression levels between different cell types or in different
culture conditions was described by Mann and co-workers in
2006 (Kratchmarova et al., 2005; Mann, 2006). Stable-isotope
labeling in cell culture (SILAC) is based on the metabolic
labeling of proteins with different variants of one or two amino
acids, resulting in a mass difference between proteins isolated
from different culture conditions (Forsman et al., 2008; Ong
and Mann, 2006). Mass spectrometric analysis enables the
relative quantification of the amounts of individual proteins
expressed by the cells. This method has since been used to
explore the differences in the proteome between hBMSCs from
different sources and under different conditions (Kratchmarova
et al., 2005).
The aim of the present study was to use a quantitative
proteomics method to identify one ormoremembrane proteins
that can be used as markers to identify hBMSCs undergoing
osteogenic differentiation in vitro.Materials and methods
The present study was performed in three steps. In the
initial exploratory phase, hBMSCs isolated from bone marrow
were metabolically labeled, during expansion or osteogenic
differentiation, with arginine (Arg) and lysine (Lys) containing
either a normal 12C carbon (light isotope) or a 13C carbon (heavy
isotope). The membrane proteins were subsequently isolated
and their relative expressions, in the two culture conditions,
were quantified by mass spectrometry (MS). In this step, one
hBMSC donor was used (n = 1). In the second step, the dif-
ference in expression of a few selected markers, between cells
undergoing expansion or osteogenic differentiation, was vali-
dated by flow cytometry or ELISA after one, two and three
weeks. In a third and final step, the lineage specificity of three
candidate markers was investigated. The expression of these
candidate markers during chondrogenic and adipogenic
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one and two weeks. In steps two and three, three different
hBMSC donors were used (n = 3).
Stem cell isolation and culture
Bone marrow from the iliac crest was obtained from patients
undergoing surgical spinal fusion at Sahlgrenska University
Hospital (ethical approval 532-04). From the biopsies, a
mononuclear cell population was isolated by density gradient
centrifugation using Vacutainer CPT tubes (Becton, Dickinson
and Company (BD), Franklin Lakes, USA) prefilled with Ficoll
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden), according
to the manufacturer's instructions. The mononuclear cell
fraction was then seeded in tissue culture flasks at a density of
approximately 250,000 cells/cm2. After 24 h, the flasks were
rinsed with Dulbecco's modified Eagles medium-low glucose
(DMEM-LG) (Thermo Fisher Scientific, Waltham, USA) and
unattached cells were discarded. The adherent cells
were then expanded in DMEM-LG supplemented with 2 mM
L-glutamine (Life Technologies, Carlsbad, USA), 1× penicillin–
streptomycin (PEST; Thermo Fisher Scientific), 10 ng/mL
human recombinant fibroblast growth factor beta (FGF-β, Life
Technologies) and 10% fetal calf serum (FCS) (Sigma-Aldrich,
Missouri, USA) and hBMSCs were enriched through culture.
During expansion, cells were passaged at 80% confluency using
0.05% trypsin with EDTA (Life Technologies) and reseeded at a
density of approximately 8,000 cells/cm2.
Multipotency assay
To verify the multipotency of the isolated hBMSCs, the
cells were induced to differentiate into the osteogenic,
chondrogenic and adipogenic lineages. The cells were differ-
entiated in passages 5–6 in either monolayer or pellet mass
culture. The media were changed three times a week and the
cells were cultured for one and two weeks before harvesting.
Multipotency culture
Osteogenic differentiation model. hBMSCs were trypsinized,
counted and reseeded at 5,000 cells/cm2 and placed in
osteogenic media 1% L-glutamine (2 mM; Life Technologies),
1% PEST (Thermo Fisher Scientific), 10% FCS (Sigma-
Aldrich), 45 mM ascorbic acid (Sigma-Aldrich), 20 mM
B-glycerophosphate (Sigma-Aldrich) and 1 μM dexametha-
sone (Sigma-Aldrich) in DMEM-LG (PAA Laboratories, Linz,
Austria).
Chondrogenic differentiation model. hBMSCs were tryp-
sinized, counted and reseeded at a density of 20,000 cells/cm2
in monolayer culture or in pellet mass culture (200,000 cells/
pellet) with chondrogenic-inductive media; DMEM-HG (PAA
Laboratories) supplemented with 5.0 μg/mL linoleic acid
(Sigma-Aldrich), 1× insulin, transferrin and selenium (ITS-G
concentrate, Life Technologies), 1.0 mg/mL human serum
albumin (Equitech-Bio, Kerrville, Tex., USA), 10 ng/ml trans-
forming growth factor β1 (TGF-β1) (R&D Systems, Abingdon,
UK), 10−7 M dexamethasone (Sigma-Aldrich), 14 μg/mL ascor-
bic acid (Sigma-Aldrich) and 1% PEST (PAA Laboratories). The
cells for the pellet mass culture were placed in a conicalpolypropylene tube and centrifuged at 500 ×g for 5 min, after
which the pellet at the bottom of the tube was gently
loosened.
Adipogenic differentiation model. hBMSCs were trypsinized,
counted and reseeded at a density of 5,000 cells/cm2 in
adipogenic-inductive media; DMEM-LG (PAA Laboratories)
supplemented with 1% L-glutamine (2 mM; Life Technologies),
1% PEST (Thermo Fisher Scientific), 20% FCS, 5.0 μg/mL insulin,
10−6 M dexamethasone, 0.5 mM isobutylmethylxathine and
60 μM indomethacin (all from Sigma-Aldrich).
Histology
After either one or two weeks of differentiation, cells in
monolayer or pellet mass culture were fixated in Histofix™ and
stained for histological evaluation. Osteogenically differentiat-
ed cells were stained using Alizarin Red (Sigma-Aldrich A5533,
2.0% in ddH2O for 5 min). Chondrogenically differentiated cells
were stained using Alcian Blue-van Gieson (Sigma-Aldrich
A-3157, 0.5% Alcian Blue in 0.5% acetic acid for 30 min) or
Safranin O (Sigma-Aldrich S-8884, 0.1% for 5 min, Fast Green
FCF Sigma-Aldrich F-7252 0.01% for 3 min). Adipogenically
differentiated cells were stained using Oil Red O solution
(Sigma-Aldrich O0625, 0.5% in isopropanol for 30 min).
Gene expression
Total RNA was isolated from the samples using an RNeasy
mini kit (Qiagen, Hilden, Germany) and RNA concentration was
measured with an ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE). 100 ng of total RNA was
transcribed to cDNA using TaqMan Reverse Transcription
reagents and random hexamer primers (Life Technologies).
The real-time qPCR reaction was performed using cDNA
equivalent to 2.5 ng RNA and the TaqMan Universal PCR master
mixture with 1× assay-on-demand mixes of primers and
TaqMan MGB probes. All samples were analyzed in duplicate
and PCR was performed using the 7900HT real time PCR
System (Life Technologies). The assays used in this study were
(catalog number in brackets): RUNX2 [Hs00231692_m1], OCN
[Hs00609452_g1], lipoprotein lipase (LPL) [Hs00173425_m1],
peroxisome proliferator-activated receptor gamma (PPARG)
[Hs00234592_m1], sex-determining region Y-box 9 (SOX9)
[Hs00165814_m1], aggrecan (AGCAN) [Hs00153936_m1] and
18s [4310893E] as a reference gene. The relative gene
expression was evaluated by the 2−ΔΔCt method in GenEx
Enterprise 5.2.3.13 (MultiD analyses, Gothenburg, Sweden).
Isotope labeling during osteogenic differentiation
At passage 5, the cells were trypsinized, counted, reseeded
at 5,000 cells/cm2 and placed in either osteogenic heavy
isotope media (10% dialyzed FCS (Life Technologies), 45 mM
ascorbic acid, 20 mM B-glycerophosphate, 1 μM dexametha-
sone, 0.1 mg/mL 13C6-arginine and 0.1 mg/mL 13C6-lysine
(Life Technologies) in DMEM-LG) to induce differentiation or
control light isotope media (10% dialyzed FCS, 45 mM ascorbic
acid, 0.1 mg/mL 12C6-arginine and 0.1 mg/mL 12C6-lysine in
DMEM-LG) supporting normal cell expansion. The cells were
cultured for 2 weeks before harvesting. This time period is
equivalent to four to five cell doublings, which would give a
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amino acids (Ong and Mann, 2006).Membrane protein isolation
Membrane proteins were isolated by sub-cellular fractionation
through serial centrifugation. Briefly, after detachment by
scraping, the cells were washed twice in cold PBS by cen-
trifugation at 1000 ×g. The pelleted cells were then re-
suspended in hypotonic buffer (20 mM KCl, 10 mM HEPES
pH 7.4) and incubated on ice for 2 min. The membrane
fraction and organelles were pelleted by centrifugation at
1000 ×g, re-suspended in homogenization buffer (255 mM
sucrose, 1 mM EDTA, 20 mM HEPES pH 7.4) and treated in a
glass homogenizer. Dense material was removed by centrifu-
gation at 14,000 ×g for 5 min. The protein concentration of the
supernatant was subsequently measured using a BCA assay and
the undifferentiated and differentiated samplesweremixed at
a 1:1 protein ratio. The membrane proteins in the pooled
sample were isolated by ultra-centrifugation at 150,000 ×g for
3 h at 4 °C. Lastly, the pellet was re-suspended in 100 mM
Na2CO3 pH 11, incubated for 90 min at 4 °C and then
centrifuged at 150,000 ×g for 2 min.Sample preparation and mass spectrometry
The sample of isolated membrane proteins was split in two
and treated as technical duplicates throughout the analysis.
The samples were dissolved in 1× LDS Sample buffer (Novex,
Life Technologies, CA USA), heated at 70 °C for 10 min and
separated on an SDS-PAGE gel (Life Technologies). Proteins
were stained with Coomassie-Blue (Colloidal Blue, Life
Technologies) and the protein-containing lanes were excised
and divided into 15 equally sized gel pieces per sample.
Individual gel pieces were subjected to in-gel digestion with
trypsin following an automated protocol on a BioMek 2000
workstation (Beckman Coulter) equipped with a vacuum
manifold. Ninety-six well plates supplemented with a 7 μL
volume of C18 reversed phase chromatographic resin were
used for vacuum filtration and sample clean-up. The work
flow essentially followed the protocol previously described
by Forsman et al. (Forsman et al., 2008; Maguer-Satta et al.,
2011), with the following exceptions. Peptide extraction was
performed twice with 0.2% trifluoroacetic acid (TFA) to
allow for peptide binding to the C18 resin of the filter plates
and peptides were eluted twice in 40 μL of 60% acetonitrile
in 0.1% TFA. The combined extracts were evaporated to
dryness in a vacuum centrifuge and, prior to LC–MS/MS
analysis, the samples were redissolved in 20 μL of 0.1%
formic acid. Online peptide separation was performed on a
150 × 0.075 mm fused silica column (Zorbax 300-SB-C18,
Agilent technologies) with a 130 min gradient from 3 to 50%
ACN, 0.1% formic acid at a flow rate of 200–300 nL/min.
Mass analyses were performed with a hybrid linear ion trap
FT-ICR mass spectrometer equipped with a 7 T ICR magnet
(LTQ-FT; Thermo Electron, Bremen, Germany). The mass
spectrometer was operated in a data-dependent mode to
switch automatically between MS and MS/MS acquisition.
Survey MS spectra (from m/z 350 to 1500) were acquired in
the Fourier transform ion cyclotron resonance (FT-ICR) andthe three most intense ions in each FT scan were fragmented
and analyzed in the linear ion trap (LTQ).MS data analysis
RawMS fileswere analyzed usingMaxQuant software (Cox et al.,
2009; Cox and Mann, 2008) (version 1.0.14.11). MS/MS spectra
were searched against the decoy International Protein Index
(IPI)-human database version 3.62 containing both forward and
reverse protein sequences, using the Mascot search engine
(Matrix Science). The search included variable modifications of
methionine oxidation and N-terminal acetylation and the fixed
modification of cysteine carbamidomethylation. Peptides of a
minimum of six amino acids and a maximum of two missed
cleavageswere allowed for the analysis. For peptide and protein
identification, the false discovery rate was set at 0.01. In the
event of the identified peptides being shared by two or
more proteins, the proteins were reported by MaxQuant as
one protein group. Ratios of heavy versus light peptides
were calculated using MaxQuant software. MaxQuant
ProteinGroups and peptides were imported to ProteinCenter
software (Thermo Fisher Scientific) and biomarker candidates
were selected based on the criterion of an expression ratio
above 2 in at least three peptides per protein. For the selected
markers, a significance outlier score was calculated by the
Significance B feature in the MaxQuant software.
Verification of protein expression
The difference in expression of several candidate markers,
8 membrane protein and one intra-cellular, during osteo-
genic (step two), adipogenic and chondrogenic (step three)
differentiation compared with undifferentiated cells was
validated using an independent method. The expression of
the selected membrane proteins was confirmed by flow
cytometry and, for the intracellular protein of interest, the
difference in expression between the undifferentiated
and differentiated state was confirmed using ELISA. At
passage 5, the cells from three different hBMSC donors
were trypsinized, counted and reseeded in osteogenic-,
adipogenic-, chondrogenic- or control media, as described
above. The cells were then cultured for up to three weeks
before harvesting and the media were changed twice a
week. After one, two or three weeks, samples were
isolated for flow cytometry and ELISA.
ELISA
In order to verify the result demonstrated in the MS
analysis, an ELISA was performed. At each time point, cells
were lysed using RIPA lysis buffer (50 mM Tris HCL pH 8,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS
(Sigma Aldrich)) with protease inhibitor added (Roche Diag-
nostics Corporation, Indiana, USA). The levels of crystalline-αB
(CRYaB) were analyzed using sandwiched ELISA (Enzo Life
Sciences, NY, USA), according to the manufacturer's instruc-
tions. Briefly, the plate was coated with a capture antibody
over night, after which the cell lysate was added to the wells.
After 1 h of incubation at RT, the plate was washed multiple
times and the detection antibody and the SA-HRP conjugate
were subsequently added. Finally, the TBM substrate was
Table 1 Proteins upregulated in hBMSCs undergoing osteogenic differentiation.
Results obtained from the MaxQuant analysis, demonstrating 52 proteins with a SILAC ratio above 2. Highlighted proteins were
selected for validation in step two.
Official
gene
symbol
Protein name Mean SILAC
ratio
Total
number of
identified
peptides
Number of
uniqe
peptides
Ratio of
variability
% (CV)
ANXA5 annexin A5 27.43 26 26 42
SLC44A1 (CD92) choline transporter-like protein 1 15.90 4 4 41
ALPL alkaline phosphatase. tissue-nonspecific isozyme isoform
1 precursor
13.78 17 17 50
ANXA1 annexin A1 11.85 27 27 51
MME (CD10) neprilysin 9.42 6 6 29
ANXA6 annexin A6 isoform 1 8.87 51 2 56
CRYAB alpha-crystallin B chain 7.90 5 5 27
EPHX1 epoxide hydrolase 1 precursor 7.43 20 20 48
ANXA6 annexin A6. isoform CRA_c 7.38 2 2 22
HSPB1 heat shock protein beta-1 6.96 6 6 19
S100A11 protein S100-A11 6.47 7 7 45
GNG5 guanine nucleotide-binding protein G(I)/G(S)/G(O)
subunit gamma-5 precursor
6.24 3 3 13
ALCAM (CD166) CD166 antigen isoform 1 precursor 5.49 18 18 50
ANXA4 annexin A4 5.38 12 12 31
ANXA11 Annexin A11 5.08 6 6 61
CPNE3 copine-3 4.62 3 2 18
ITGA5 (CD49e) integrin alpha-5 precursor 4.42 12 12 37
ANXA2 annexin A2 isoform 1 4.35 37 37 86
AHNAK neuroblast differentiation-associated protein AHNAK
isoform 1
4.04 87 87 27
MYO1C Myosin-Ic 3.88 21 21 35
ANPEP (CD13) aminopeptidase N precursor 3.79 24 24 33
YWHAZ 14-3-3 protein zeta/delta 3.64 5 4 60
GNG12 guanine nucleotide-binding protein G(I)/G(S)/G(O)
subunit gamma-12 precursor
3.39 6 6 32
CFL1 cofilin-1 3.35 3 3 7
PPAP2B lipid phosphate phosphohydrolase 3 3.12 3 3 35
APOL2 apolipoprotein L. 2 3.10 3 3 6
PDGFRB (CD140b) platelet-derived growth factor receptor beta precursor 3.04 5 5 26
STOM erythrocyte band 7 integral membrane protein isoform a 3.04 9 9 21
ATP1B3 sodium/potassium-transporting ATPase subunit beta-3 3.00 3 3 66
GAPDH glyceraldehyde-3-phosphate dehydrogenase isoform 1 2.82 9 9 49
PFN1 profilin-1 2.80 5 5 11
MCAM (CD146) cell surface glycoprotein MUC18 precursor 2.79 3 3 6
CD97 CD97 antigen isoform 1 preproprotein 2.74 3 3 12
GNB2 guanine nucleotide-binding protein
G(I)/G(S)/G(T) subunit beta-2
2.70 10 4 15
ATP1A1 sodium/potassium-transporting ATPase subunit alpha-1
isoform a
2.60 20 20 19
RRAS ras-related protein R-Ras precursor 2.57 3 3 9
GNB4 guanine nucleotide-binding protein subunit beta-4 2.49 7 2 2
GNAI2 Galphai2 protein 2.45 8 6 15
PPIA peptidyl-prolyl cis-trans isomerase A 2.44 3 3 7
LDHA L-lactate dehydrogenase A chain isoform 3 2.43 8 8 23
NPTN neuroplastin isoform b precursor 2.40 3 3 21
GNB1 guanine nucleotide-binding protein G(I)/G(S)/G(T)
subunit beta-1
2.36 9 6 18
CD276 CD276 antigen isoform a precursor 2.35 4 4 34
CALM3 calmodulin 3 (phosphorylase kinase. delta). isoform
CRA_e
2.30 3 3 18
(continued on next page)
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Table 1 (continued)
Official
gene
symbol
Protein name Mean SILAC
ratio
Total
number of
identified
peptides
Number of
uniqe
peptides
Ratio of
variability
% (CV)
S100A10 protein S100-A10 2.28 4 4 97
SLC16A3 monocarboxylate transporter 4 2.27 4 4 20
ATP2B4 Plasma membrane calcium-transporting ATPase 4 2.26 10 5 30
CD59 CD59 glycoprotein preproprotein 2.22 5 5 14
BSG (CD147) basigin isoform 1 precursor 2.21 3 3 51
DPYSL2 dihydropyrimidinase-related protein 2 isoform 2 2.16 5 5 37
MSN moesin 2.15 6 6 39
CAV1 caveolin-1 isoform alpha 2.13 8 2 28
158 C. Granéli et al.added and the absorbance at 450 nmwas measured (Multiscan
FC plate reader, Thermo Fisher Scientific).
Flow cytometry
The result obtained from the MS analysis was validated
using flow cytometry. To achieve a single cell suspension
after differentiation or control media culture, the ECM was
degraded by collagenase (Type 2, Worthington Biochemical
Corporation, NJ, USA) for 20–30 min. Subsequently, the cells
were detached by trypsinization, resuspended and washed
twice with FACS buffer consisting of phosphate buffered saline
(PBS) with 5% FCS, 1% bovine serum albumin (BSA) and 2 mM
EDTA (Sigma Aldrich). The cells were then stained using the
antibodies or the appropriate isotype controls (BioLegend,
California, USA) listed in Table 1. The cells were incubatedwith
a saturated antibody solution in the dark on ice for 30 min,
then washed twice in cold FACS buffer and subsequently
resuspended in 150 μL of cold FACS buffer and kept on ice until
acquisition. The FACS analysis was carried out on the BD FACS
ARIA flow cytometer, using Comp Beads plus (BD) to calculate
the compensation and FlowJo software (Tree Star, Oregon,
USA) for analysis. Cells were acquired and gated by forward
scatter (FSC) and side scatter (SSC) to exclude debris and cell
aggregates. To calculate the percentage of cells positive for
each of the selectedmarkers, amaximum of 0.5% false positive
gate was set using the isotype control.
Statistical analysis
All the statistical analyses were performed in PASW Statistics
18.0 using either a one-way ANOVA (gene expression) or
independent t-test for normally distributed data. The differ-
ence in protein expression during validation by flow cytometry
was analyzed using the percentage of positive cells for each
marker. The mean of all observations (irrespective of time
point) for each marker was calculated and compared with the
undifferentiated control.
Results
hBMSCs isolated from four different donors, in passages 5–6,
positive for CD166 and CD105 (97.3 ± 5.2% and 99.0 ± 1.1%
respectively) and negative for CD45 and CD34 (0.3 ± 0.3%
and 0.3 ± 0.5% respectively), were used in this study. Usingan exploratory approach, proteins differently expressed in
osteogenic differentiating hBMSCs were identified using the
SILAC method. The quantitative MS analysis was performed
on one SILAC sample, which was divided into two technical
replicates to reduce the effects of under-sampling in the
mass spectrometric analysis. Based on the results of this
experiment, 9 proteins were selected for further validation
of their differential expression during osteogenesis. The
expression levels of several membrane proteins and one
intra-cellular protein were measured at several time points
in three independent biological replicates by flow cytometry
or ELISA. Finally, the lineage specificity of three candidate
markers was investigated.
Multipotency assay
hBMSCs, in passages 5–6, were induced to differentiate into
osteoblasts, adipocytes or chondrocytes in a multipotency
assay. Samples from all donors were positively stained for
each specific lineage staining at the later time point (Fig. 1).
Gene expression analysis of the chondrogenic specific
markers, SOX9 and AGCAN, the osteogenic specific markers,
OCN and RUNX2, and the adipogenic specific markers, LPL and
PPARG, displayed increased expression over time (Fig. 2).
Quantification of protein expression
The MS analysis of the membrane protein fraction that was
isolated from undifferentiated hBMSCs and hBMSCs under-
going osteogenic differentiation generated data from which
991 protein groups were identified at a 1% false discovery rate
(FDR) by database searches against the human IPI database
using the Mascot search engine. Further data reduction by
filtering proteins identified by at least two unique peptides
resulted in the identification of 594 proteins.
When sorted in the David Bioinformatic database functional
annotation tool (Dennis et al., 2003; Jones et al., 2002) using
the gene ontology (GO) FAT classification based on cellular
compartment (CC), 497 of the identified proteins were also
present in the DAVID database and the largest fraction (approx.
1/3) of these proteins was annotated as membrane-associated
proteins. However, despite using a subcellular fractioning
method for the isolation of membrane proteins, several
non-membrane-associated proteins were identified by the
Figure 1 Multipotency assay histology. Top. Representative images from tri-lineage assay of three different donors at 1 week
(upper panel) and two weeks (lower panel) of differentiation. (A & E) Chondrogenically differentiated cells in monolayer stained
using Alcian Blue–van Gieson (ABvG). (B & F) Chondrogenically differentiated cells in monolayer stained using Safranin O (Saf-O). (C
& G) Osteogenically differentiated cells stained using Alizarin Red. (D & H) Adipogenically differentiated cells stained using Oil Red
O. Bottom. Chondrogenically differentiated cells in pellet stained using (I) ABvG and (J) Saf-O.
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ratios was performed using MaxQuant software and a mean
protein ratio was calculated for each identified protein based
on at least three peptide ratios. This generated a list of 52
quantified proteins with an expression ratio above 2 (Table 1).
Of these proteins, we found 11 membrane proteins and two
intracellular proteins of interest, due to their large differ-
ences in expression between the two conditions.Surface protein expression
The MS-based analysis demonstrated that 11 membrane
proteins were differentially expressed when comparing
undifferentiated and osteogenically differentiated hBMSCs(Table 1). CD10 (neprilysin) and CD92 (choline transporter-like
protein 1) showed the largest relative expression change
between the differentiated and undifferentiated states, with
a ratio of 9.4 and 15.9 respectively. Moreover, the expression
of CD49e (integrin alpha-5) was 4.6 times higher in differen-
tiated hBMSCs compared with the undifferentiated cells.
Other CD markers found to be upregulated, albeit to a lesser
degree, in differentiated cells were CD13, CD59, CD97,
CD140b, CD146, CD147 and CD267.Intracellular protein expression
We also identified two non-membrane proteins with
increased expression levels in differentiated hBMSCs
Figure 2 Multipotency gene expression. The development over time in gene expression of lineage specific markers analyzed by
qPCR. The expressions of (A) SOX9 and (D) AGCAN have been analyzed during chondrogenic differentiation. The expressions of (B) OCN
and (E) RUNX2 have been analyzed during osteogenic differentiation and the expression of (C) LPL and (F) PPARG have been analyzed
during adipogenic differentiation. * indicates a statistical difference (p b 0.05).
160 C. Granéli et al.compared with undifferentiated cells (Table 1). As expected,
the expression level ALP was increased, approximately 14
times in the differentiated cells. Interestingly, the protein,
crystalline aβ (CRYaB), which is relatively unknown in the
context of osteogenesis, was upregulated almost 8 times.
Validation of differentially expressed proteins
during osteogenesis
Surface marker validation by flow cytometry
In order to verify the MS-based proteomic identification
of several surface markers, 8 of the 10 differentially ex-
pressed CD markers were selected for confirmation by flow
cytometry. Three of the CD markers were not chosen due to
previously published data on these markers, the smallTable 2 Flow cytometry MFI ratios between osteogenically
differentiated and undifferentiated hBMSCs.
The median fluorescence intensity (MFI) ratios, calculated
between differentiated and undifferentiated cells, of selected
CD markers after 1, 2 and 3 weeks. Highlighted proteins were
selected for lineage specificity validation in step three. *
indicates a statistical difference of p b 0.05.
CD
marker 1w 2w 3w 1w 2w 3w 1w 2w 3w
CD10* 19.9 8.0 3.4 10.3 4.4 2.9 8.3 14.0 7.7
CD49e* 1.0 5.7 3.4 0.5 1.6 7.9 2.1 1.8 5.0
CD59 1.1 0.8 1.3 0.7 0.8 0.9 0.8 0.8 0.9
CD92* 3.9 2.5 2.1 3.0 2.1 1.9 3.0 2.5 1.7
CD105 0.4 1.1 0.3 0.6 2.0 2.5 0.6 0.6 0.7
CD140b* 2.8 3.8 1.2 3.4 2.8 2.5 2.4 1.4 0.8
CD146 2.8 1.1 1.0 1.2 1.6 1.8 1.6 1.1 0.8
CD147* 1.9 1.9 2.6 0.9 1.3 1.8 1.7 1.8 2.9
CD166 1.6 2.7 3.7 1.5 2.4 1.2 3.2 2.2 2.3
MFI Ratio (osteogenic differentiated/undifferentiated)
Don1 Don 2 Don 3number of identified peptides or the lack of suitable flow
cytometry antibodies. The protein expression in hBMSCs
from three individual donors was analyzed and cells were
either expanded or induced to undergo osteogenic differ-
entiation and were harvested after one, two and three
weeks. In addition to the above-mentioned markers, the
expression of the hBMSC-associated CD marker, CD105, was
analyzed in order to evaluate changes in the hBMSC
phenotype of the cells during the differentiation process.
The median fluorescence intensity MFI ratios for osteo-
genically differentiated/undifferentiated hBMSCs for
all three donors are presented in Table 2. For the CD
markers of prime interest, CD10 and CD92, the MFI of
differentiated cells was significantly higher than that of the
undifferentiated cells at all 3 time points. The MFI ratio for
CD10 was continuously high over time, whereas a declining
trend could be seen for CD92. The expression of CD166 was
approximately twice as high in differentiated cells com-
pared with undifferentiated cells and remained stable over
time. The marker CD49e displayed a significantly increased
MFI ratio in osteogenically differentiated hBMSCs compared
with undifferentiated controls, revealing the largest difference
after three weeks. In contrast, the MFI ratios for CD140b and
CD146 were highest after one week of differentiation. Both
CD140b and CD147 displayed significantly increased MFI
in osteogenically differentiated hBMSCs compared with undif-
ferentiated hBMSCs. As expected, the expression of hBMSC
marker CD105 was higher in the undifferentiated cells at all
times. Histograms (control-sample overlays) of CD10 and CD92
are shown in Supplementary Fig. 1.
Intracellular protein CRYaB validation by ELISA
The expression of the intracellular protein, CRYaB,
in osteogenically differentiated and undifferentiated
hBMSCs, was analyzed using a sandwich ELISA. The
expression of CRYaB was significantly upregulated in all
161Novel markers of osteogenic and adipogenic differentiationthree donors during the osteogenic differentiation of the
hBMSCs, with a mean fold change of 1.9 ± 0.5, 2.7 ± 0.8 and
3.5 ± 0.9, after one, two and three weeks of cell culture
respectively, compared with the undifferentiated hBMSCs
(Fig. 3).
Lineage specificity of candidate markers
CD10 and CD92 expression during chondrogenic and
adipogenic differentiation
In order to evaluate the lineage specificity of the selected
markers, the expression of CD10 and CD92 was studied by
flow cytometry of hBMSCs cultured in chondrogenic and
adipogenic differentiation media. For chondrogenically
induced hBMSCs, the MFI ratio of CD10, but not CD92, was
significantly increased compared with undifferentiated
controls (Table 3). The same was true for CD10 but also for
CD92 in adipogenically differentiated hBMSCs compared with
undifferentiated hBMSCs (Table 3). Histograms (control-
sample overlays) for CD10 and CD92 are shown in Supple-
mentary Fig. 2. A summary of the expressions of all markers
based on the mean MFI ratio from all donors, for each of the
three lineages, is shown in Table 4. Here, two CD markers,
CD10 and CD92, had continuous highly upregulated (++, mean
MFI ratio N 3) or upregulated (+, mean MFI N 1.5) expression
in osteogenically differentiated cells. These two markers
were also upregulated during adipogenic differentiation but
not during chondrogenic differentiation (0, 0.7 b mean MFI
ratio b 1.5).
CRYaB expression during chondrogenic and
adipogenic differentiation
The expression of CRYaB did not demonstrate any significant
differences between adipogenically/chondrogenically differen-
tiated hBMSCs and their undifferentiated controls (Fig. 4). The
expression of the CRYaB marker (based on the mean from all
donors) for each of the three lineages is summarized in Table 4.
Discussion
The GO classification of the isolated proteome confirms that
subcellular fractioning is a suitable method for isolating
membrane-bound and membrane-associated proteins. This
is an important aspect of the reliability of the membrane
proteins that have been identified using this method. The
largest part of the isolated proteins in this study was
annotated as plasma membrane proteins.
In the first exploratory part of the present study, several
surface proteins were found to be upregulated during the
osteogenic differentiation of hBMSCs. After validating the
expression of selected surface markers by flow cytometry,
new information about their expression patterns during
osteogenic differentiation was revealed. CD49e was upregulat-
ed upon osteogenic differentiation, with a more pronounced
difference after three weeks of differentiation. Hamidouche et
al. (2009, 2010) have demonstrated that CD49e, also known as
integrin alpha-5, is not only involved in the differentiation
process of hBMSCs towards the osteogenic lineage but that the
stimulation of CD49e also promoted an increase in the amount
of bone matrix in vivo. Further, the gene expression of CD49e
has also been shown to be increased during dexamethasone-induced osteogenic differentiation (Baksh et al., 2007), which
was also demonstrated in our study but at the level of protein
expression.
It is interesting to note that the commonly used hBMSC
and hMSC marker, CD166, showed a higher expression
in osteogenically differentiated cells compared with undif-
ferentiated cells. This increase in expression was also
recently demonstrated in hBMSCs undergoing both osteo-
genic and adipogenic differentiation by Niehage and
co-workers (Fort and Lampi, 2011; Niehage et al., 2011).
Their results are supported by the data presented in this study
and raise the question of the suitability of CD166 as amarker of
undifferentiated hBMSCs. In contrast, another hBMSC marker,
CD105, analyzed in the CD marker validation step, was
confirmed as a more accurate marker of undifferentiated
cells, since, as expected, its expression decreased within one
week of induced differentiation.
Four surface markers, CD59, CD140b, CD146 and CD147,
all showed MS analysis SILAC ratios of between two and
three. In the validation step, CD140b and CD147 displayed
higher expressions in osteogenically differentiated cells com-
pared with undifferentiated cells. For CD140b, a general trend
towards similar expression between the two culture conditions
could be seen as the differentiation progressed over time.
CD140b, also called platelet-derived growth factor receptor
beta (PDGFR-β), acts as a receptor for the platelet-derived
growth factor (PDGF), which is involved in the complex network
for the regulation of bone formation (Arvidson et al., 2011).
PDGFR-β was recently shown to regulate BMSC proliferation
andmigration, aswell as suppressing osteogenic differentiation
by reducing ALP activity and mRNA levels (Tokunaga et al.,
2008). In the present study, the results showed a significantly
higher expression of CD140b in the osteogenically differentiat-
ed hBMSCs, compared with the undifferentiated cells. Even
though this difference decreased over time, it contradicts to
some extent the results previously presented by Tokunaga
et al. In contrast to the decrease in expression over time seen
for CD140b, the expression of the extracellular matrix
metalloproteinase inducer, CD147, which has recently been
suggested as a therapeutic marker of human osteosarcoma
(Lv, 2013), was from one to three weeks of osteogenic
differentiation.
Of the 11 markers identified by our MS analysis, CD10
and CD92 displayed the highest SILAC ratios between
osteogenically differentiated and undifferentiated cells.
Their upregulation during the osteogenic differentiation of
hBMSCs was confirmed by flow cytometry, where the two
proteins again showed the largest difference in expression
between osteogenically differentiated and undifferentiated
cells. Further, during the validation of the lineage specificity
of CD10 and CD92, it was revealed that the expression of both
markers was also significantly upregulated during adipogenic
differentiation. However, there was no increase in the ex-
pression of CD92 and a small but yet significant increased
increase in CD10 expression during chondrogenic differentiation
compared with undifferentiated cells.
CD10 is a cell-surface metallo-endopeptidase initially
associated with leukocytes. This enzyme has been used in
diagnostics as a marker of human acute lymphocytic leukemia
(Gronthos et al., 2001; Maguer-Satta et al., 2011), but it has
also been described as a surface marker present on MSCs
isolated from both bone marrow (Jones et al., 2002; Michel
Figure 3 CRYaB expression during osteogenic differentiation. Relative CRYaB protein expression in osteogenically differentiated or
undifferentiated cells determined by ELISA after 1, 2 and 3 weeks of. * indicates a statistical difference (p b 0.05).
Table 4 Summary of differentiation marker expression.
Summary of the differentially expressed markers during
osteogenic, chondrogenic and adipogenic differentiation of
hBMSCs. Highly upregulated expression (++) is defined as a
mean MFI ratio above three, upregulated (+) as a mean MFI
ratio above 1.5 and no difference in expression (0) between
differentiated and undifferentiated cells defined as a mean
MFI ratio of less than 1.5 but higher than 0.7. A mean MFI
ratio of less than 0.7 is defined as downregulated expression
(–) in differentiated cells.
CD marker 1w 2w 3w
Osteogenic
CD10 ++ ++ ++
CD49e 0 + ++
CD59 0 0 0
CD92 ++ + +
CD105 – 0 0
162 C. Granéli et al.and Bakovic, 2009) and adipose tissue (Gronthos et al., 2001;
Han et al., 2003). Several peptides participating in osteogen-
esis, such as calcitonin, osteostatin and osteogenic growth
peptide (OPG), have been identified as substrates for CD10
(Ruchon et al., 2000). It can be speculated that an increase
in the presence of these osteogenic peptides during differen-
tiation would lead to an upregulation of the CD10 protein and
its enzymatic activity. CD10 has been reported in rat articular
cartilage and in human osteoarthritic (OA) chondrocytes, but its
function in cartilage is still relatively unknown. However, it is
known that CD10 is increased in dedifferentiated chondrocytes,
which have a surface marker profile similar to that of their
progenitors, the BMSCs (Diaz-Romero et al., 2004). A recent
study was unable to discern any differences in chondrogenic
potential between synovial-derived MSCs, positive or negative
for CD10 (C. B. Chang et al., 2013). Moreover, like the present
study, no evidence was presented in the latter publication
to suggest that CD10 is a valid marker of chondrogenic
differentiation.
It has been suggested that the activity of CD10 has an
impact on body mass and fat accumulation and it has been
identified as a regulator in the development of obesity
(Becker et al., 2010). Due to the close relationship in lineage
differentiation, the similarities in CD10 expression in adipo-
genically and osteogenically differentiated cells come as noTable 3 Flow cytometry MFI ratios between
chondrogenically or adipogenically differentiated and undiffer-
entiated hBMSCs.
The median fluorescence intensity (MFI) ratios, calculated
between differentiated and undifferentiated cells, of CD10 and
CD92 after 1 and 2 weeks.
Don 1 Don 2 Don 3
CD marker 1w 2w 1w 2w 1w 2w
MFI ratio (chondrogenic differentiated/undifferentiated)
CD10 ⁎ 1.5 1.3 1.6 1.3 1.5 1.3
CD92 1.1 1.0 1.0 0.9 1.0 1.0
MFI ratio (adipogenic differentiated/undifferentiated)
CDIO ⁎ 8.2 13.2 15.0 7.4 2.0 3.2
CD92 ⁎ 1.5 1.2 2.3 1.7 2.1 1.6
⁎ Indicates a statistical difference of p b 0.05.surprise, but, to the authors' knowledge, the present study
is the first to demonstrate the expression of CD10 as up-
regulated in osteogenically and adipogenically differenti-
ated hBMSCs.CD140b ++ + 0
CD146 + 0 0
CD147 0 + +
CD166 + + +
CRYaB ++ ++ ++
Chondrogenic
CD10 0 0
CD92 0 0
CRYaB 0 0
Adipogenic
CD10 ++ ++
CD92 + 0
CRYaB 0 0
++ Highly upregulated in differentiated cells (mean MFI
ratio N 3).
+ Upregulated in differentiated cells (mean MFI ratio N 1.5).
− Downregulated in differentiated cells (mean MFI ratio b 0.7).
0 No change between differentiated and undifferentiated cells.
Figure 4 CRYaB expression during chondrogenic and adipogenic differentiation. Relative CRYaB protein expression in chondrogenically,
adipogenically differentiated or undifferentiated cells determined by ELISA after 1 and 2 weeks.
163Novel markers of osteogenic and adipogenic differentiationCD92 is also known as choline transporter-like protein 1
(CTL1) and its main function is to transport choline, which is
then incorporated into phosphatidylcholine (PC), across the
cell membrane (Michel and Bakovic, 2009; Nakamura et al.,
2010). In vivo, PC is found in the lipid fraction in the
calcification front during both intramembranous and endo-
chondral bone formation and the addition of PC to bone
graft material has been shown to increase the osteoinductivity
of the material and ALP activity in the surrounding tissue (Han
et al., 2003). Albeit speculative, it is therefore possible that
the strong upregulation of CD92 in osteogenically differen-
tiated cells, demonstrated in the present study, is related
to the increased synthesis of PC during osteogenic differen-
tiation. Furthermore, the gene expression of CD92 is up-
regulated in response to dexamethasone in the context of
choline uptake in human lung adenocarcinoma (Nakamura
et al., 2010). This is in line with the present results, as
dexamethasone was the glucocorticoid steroid used in this
study to induce differentiation. The present results extend
previous observations, demonstrating the upregulation of
CD92 in osteogenically differentiated hBMSCs at protein
level. A significant increase in CD92 expression was also
seen in adipogenically differentiated hBMSCs compared
with undifferentiated hBMSCs, a difference that was most
pronounced during the initial stages of differentiation.
There appears to be a lack of knowledge in the literature
regarding the expression of CD92 in relation to both osteo-
genically and adipogenically differentiated cells and fur-
ther studies of the mechanism via which CD92 affects the
differentiation process are needed.
The statistically significant difference in the protein
expression of CD10 and CD92 between osteogenically or
adipogenically differentiated hBMSCs and the undifferenti-
ated controls, in combination with their cellular localization
to the plasma membrane, underscores the potential of these
proteins as novel markers of mainly osteogenic and adipogenic
differentiation in vitro, which can easily be monitored by flow
cytometry, ELISA or immunohistochemistry.
In addition to the identified membrane-bound proteins,
the subcellular fractionation further isolated proteins that
were not annotated as membrane bound. The intracellular
protein, CRYaB, is a small heat shock protein belonging to
the alpha family, which is composed of two gene products,
alpha-A (acidic) and alpha-B (basic) proteins. Alpha-A is
associated with the vertebrate eye lens, while alpha-B isexpressed in many tissues and organs. The gene expression
of CRYaB has been shown to be significantly regulated in the
early stages of the chondrogenic differentiation of the
ATDC-5 chondroprogenitor cell line (Chen et al., 2005).
Further, Lambrecht et al. (2009) have reported a reduction
in CRYaB expression in dedifferentiating chondrocytes, thus
indicating that CRYaB perhaps plays a role in the chondrogenic
differentiation process. However, the present results indicate
an increase in the protein expression of CRYaB during the
osteogenic differentiation of hBMSCs. The data indicate an
osteogenic lineage specificity of thismarker, since the present
results did not reveal any upregulation of CRYaB during early
adipogenic and chondrogenic differentiation. The elevated
expression of CRYaB has previously been associated withmany
neurological diseases (Fort and Lampi, 2011; Klemenz et al.,
1991). However, relatively little is known about the role of
CRYaB in osteogenic differentiation. Furushima et al. (2002)
previously reported that CRYaB gene expression is associated
with bone metabolism, which has also been demonstrated in
a gene microarray study of hBMSCs during differentiation
into osteoblasts (Kulterer et al., 2007). Apart from this, no
specific role for CRYaB in osteogenic differentiation is known.
The role and the underlying mechanisms of this protein in the
osteogenic differentiation process therefore require further
studies.
To conclude, our results demonstrate significant differ-
ences in the proteome between osteogenically differentiated
hBMSCs and undifferentiated hBMSCs. The surface markers,
CD10 and CD92, displayed a significantly higher expression in
both osteogenically and adipogenically differentiated hBMSCs
compared with an undifferentiated control. CD10 only dis-
played a modest increase during the chondrogenic differen-
tiation of hBMSCs, whereas the expression of CD92 was
unaffected by differentiation towards this lineage. In addition,
our study further revealed that CRYaB is an intracellularmarker
specific for osteogenic differentiation due to its several fold
change increase in the osteogenically differentiated hBMSCs,
throughout a three-week culture period. Further, the present
study suggests that CD105 is a more accurate marker of un-
differentiated cells than CD166, since the latter displayed
increased expression in differentiated cells, which is of great
importance for the definition of the hBMSC population.
Taken together, the results suggest that CD10 and CD92
are surface markers of the osteogenic and adipogenic
differentiation of hBMSCs in vitro, whereas the intracellular
164 C. Granéli et al.marker, CRYaB, is specific for osteogenically differentiated
hBMSCs. Our data provide a basis for future studies of the
proteome of differentiating hBMSCs and the suitability of the
markers presented here as tools for evaluating the lineage
commitment of hBMSCs.Acknowledgments
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